NSCLC patients with elevated expression of IGF-1R show poor responses to EGFR-TKIs treatment, strongly suggesting that activation of the IGF-1R pathway is relevant to resistance against EGFR-TKIs (27). Here, IGF1R is linked to non-small cell lung carcinoma.